• 🌎 Worldwide
    • πŸ‡ΊπŸ‡Έ U.S.
    • πŸ‡¨πŸ‡¦ Canada
    • πŸ‡¬πŸ‡§ United Kingdom
    • 🌏 Asia
    • 🌍 Europe
    • 🌎 Latin America
    • 🌏 Oceania and Australasia
The Daily Marijuana Observer
SUBSCRIBE
  • Home
  • Latest
  • πŸ”’ PRO
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
  • Home
  • Latest
  • πŸ”’ PRO
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
No Result
View All Result
Home Investments

FSD Pharma to Acquire Prismic Pharmaceuticals

Canada Newswire by Canada Newswire
April 23, 2019
in Investments, Marijuana Stocks, Press Releases
Columbia Care Launches β€œ100,000,000 Ways to Break the Opioid Crisis” Initiative

Photo by freestocks.org on Pexels.com

90
SHARES
ShareShare

TORONTO, April 23, 2019 /CNW/ – FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) and Prismic Pharmaceuticals Inc. (“Prismic”), a US-based specialty R&D pharmaceutical company, announced today that they have entered into a securities exchange agreement dated April 22, 2019 (the “Agreement”) pursuant to which FSD Pharma has agreed to acquire all of the outstanding securities of Prismic (the “Transaction”). Prismic is developing novel non-addictive prescription drugs with unique safety profiles with the goal of addressing the opioid crisis based on formulations utilizing micro-palmitoylethanolamide’s (“PEA”) “entourage” effect on certain drugs impacting the endocannabinoid system.

Pursuant to the terms of the Agreement, FSD Pharma will acquire all outstanding common and preferred shares of Prismic for an aggregate purchase price of US$17.5 million (CAD$23.4 millionbased on an exchange rate of US$1 to CAD$1.3349), to be satisfied by the issuance of an aggregate of 102.7 million Class B subordinate voting shares in the capital of FSD Pharma (each, an “FSD Share”) at a deemed price of CAD$0.2275 (US$0.1704) per FSD Share representing the volume weighted average price of the FSD Shares on the Canadian Securities Exchange (the “CSE”) for the ten trading days prior to the execution of the Agreement. In addition, FSD Pharma has agreed to assume up to US$4.0 million of outstanding Prismic liabilities on terms to be mutually agreed by the two companies, some of which may, potentially, be settled by the issuance of additional FSD Shares. Additionally, all of the outstanding Prismic stock options and warrants will become exercisable into FSD Shares, with the number and exercise price of such securities to be adjusted in accordance with the Transaction’s exchange ratio.

The FSD Shares to be issued to the Prismic shareholders will be deposited into escrow at the closing of the Transaction, and be subject to an 18-month staggered time escrow release.

“This transaction symbolizes FSD Pharma’s vision of acquiring a platform company to advance research and development of FDA-approved applications of synthetic cannabinoids and other synergistic molecules,” said FSD Pharma Executive Co-Chairman & CEO, Dr. Raza Bokhari. “Led by Peter Moriarty, one of the founders of Shire Pharmaceuticals, Prismic’s management team has built a solid foundation for a specialty pharmaceutical company, and we look forward to providing them with milestone-based support in order to advance proprietary drug candidates through the various development stages. This is a very exciting day for FSD Pharma that we believe represents a paradigm shift in the development and outlook of our company.”

Peter Moriarty, Co-Founder and Chairman of the Board of Directors of Prismic, commented, “We are excited to be entering into a new phase of growth with FSD Pharma. We believe our combined resources and highly competent leadership teams will position us to execute on our clinical development programs and on delivering highly effective products that safely address pain, inflammation and neurological disorders with high unmet clinical needs.”

Prismic has exclusive worldwide licensing rights (except for Italy and Spain) to a patent-protected form of palmitoylethanolamide (micro-PEA with particle sizes of 0.6 – 10 microns), on which Prismic’s development platform is based and from which Prismic’s lead prescription drug candidate, PP-101, has been formulated. Such formulations take advantage of micro-PEA “synergistic” or “entourage” effect on certain drugs impacting the endocannabinoid system. This means that lower doses of those drugs may be administered together with micro-PEA to achieve the desired therapeutic effect. This includes the potential combination or concomitant use of micro-PEA formulations with drugs such as THC, CBD, certain anticonvulsants, and opioids where studies have indicated opioid-sparing and tolerance delaying properties of micro-PEA may impact the development of dependence in patients. Prismic’s first prescription drug candidate, PP-101, a 600 mg tablet of micro-PEA, is anticipated to commence a Phase 2/3 accelerated clinical development program in early 2020 as a concomitant medication to be administered with pregabalin (Pfizer’s Lyrica®) for the treatment of fibromyalgia.

Completion of the Transaction is subject to various closing conditions, including: the approval of the CSE, the approval of the boards of directors of FSD Pharma and Prismic, the approval of the security holders of Prismic, and completion of due diligence by the parties.

About FSD Pharma

FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company has 25,000 square feet available for production at its Ontario facility.

FSD Pharma’s facilities sit on 70 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet.

FSD Pharma’s wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017. FV Pharma’s vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

About Prismic Pharmaceuticals

Prismic is a US-based specialty pharmaceutical company dedicated to addressing the opioid crisis by developing novel non-addictive prescription drugs for the treatment of pain, inflammation, and neurological disorders, based on formulations utilizing the company’s micro-PEA development platform (palmitoylethanolamide with particle sizes of 0.6 – 10 microns). Such formulations take advantage of micro-PEA’s “synergistic” or “entourage” effect on certain drugs impacting the endocannabinoid system. This means that lower doses of those drugs may be administered together with micro-PEA to achieve the desired therapeutic effect. This includes the potential combination or concomitant use of micro-PEA formulations with drugs such as THC, CBD, certain anticonvulsants, and opioids where studies have indicated opioid-sparing and tolerance delaying properties of micro-PEA may impact the development of dependence in patients. Prismic’s first prescription drug candidate, PP-101, a 600 mg tablet of micro-PEA, is anticipated to commence a Phase 2/3 accelerated clinical development program in early 2020 as a concomitant medication to be administered with pregabalin (Pfizer’s Lyrica®) for the treatment of fibromyalgia.

Prismic was founded by three healthcare industry veterans, Zachary Dutton, Danilo Casadei Massari, and Peter Moriarty who was also one of the founders of Shire Pharmaceuticals.

Forward-Looking Information

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements: that the Transaction will represent a paradigm shift for the Company; that Prismic’s drugs under development will have the capability of addressing the opioid crisis; that the combined resources and leadership teams of FSD Pharma and Prismic will be positioned to execute on clinical development programs and on delivering highly effective products that safely address pain, inflammation and neurological disorders with high unmet clinical needs; that lower doses of certain drugs may be administered together with micro-PEAs to achieve a desired therapeutic effect; regarding the expected timing of Prismic’s Phase 2/3 accelerated clinical development program for Prismic’s PP-101 drug candidate; and regarding the Transaction terms and the expected benefits to the Company and its shareholders as a result of the proposed acquisition of Prismic. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Prismic’s proposed drug formulations may not achieve FDA or other necessary regulatory approvals; that Prismic’s micro-PEA formulations may not work as expected or at all; that the Transaction may not be approved by the CSE or the shareholders of Prismic; that the Transaction may not be completed on the terms expected or at all; that legislative changes may have an adverse effect on the business and product development of products of the Company and Prismic; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws. Statements in this release with respect to Prismic and its products have been provided by Prismic and, as at the date hereof, have not been independently verified by the Company.

Share this:

  • Click to email this to a friend (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)
Tags: CSE:HUGEFSD Pharma Inc.licensed producerOTC:FSDDFPrismic Pharmaceuticals Inc.

Get Real-Time Updates from MJobserver.com

Unsubscribe
Canada Newswire

Canada Newswire

Powered by CNW, Cision provides simultaneous distribution of news releases and multimedia to media and financial markets and feeds websites as well as social media accounts and blogs. Our expertise in content distribution has made us a trusted and integral part of the Canadian media and market landscapes. As market leader, Cision is the first place journalists and investors look for news releases from Canadian organizations, and it is the only service commercially endorsed by the TSX for newswire and financial webcast capabilities.

Related Posts

Aleafia Health Inc. (TSX: ALEF) (OTC: ALEAF) Stock News
Canada

Unifor and Aleafia Health Enter Exclusive Agreement to Support Medical Cannabis Coverage for Members

January 21, 2021
Amended: Naturally Splendid Closes Private Placement and Secures Laboratory Facility
Investments

MediPharm Labs Ships Company Record 550,000 Units in Q4 2020

January 11, 2021
Aleafia Health Inc. (TSX: ALEF) (OTC: ALEAF) Stock News
Canada

Aleafia Health Announces Third Quarter 2020 Results

November 11, 2020
The Flowr Corp. to Report Q4 and Fiscal Year-End 2018 Earnings - Cannabis Stocks News
Investments

The Flowr Corporation Announces Strategic Acquisition of Terrace Global

October 20, 2020
Canadian cannabis stock news
Canada

Sundial Expands Brand Portfolio Presence with Palmetto Available Coast-to-Coast

October 20, 2020
Amended: Naturally Splendid Closes Private Placement and Secures Laboratory Facility
Press Releases

MediPharm Labs Launches LABS CANNABIS, A New and Innovative Family of Health and Wellness Products

October 20, 2020
Load More
Next Post
Green Growth Brands Announces Conclusion of Strategic Review Process, Consent to Receivership Appointment for CBD Business, and Continuation of Cannabis Business in Florida, Massachusetts, and Nevada

Village Farms International Announces that All Growing Area at Pure Sunfarms' Delta 3 Greenhouse Now in Production/Company to Host First Quarter 2019 Conference Call Friday, May 10, 2019 at 11:00 a.m. ET

Leave a Comment! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

πŸ”Ž Search Marijuana Stocks

πŸ“° Recent News

  • American Green’s Grand Opening on Amazon is a Success
  • The Jordre Well, LLC Submits CBD-Infused Coffee Samples to Labs for Testing
  • Unifor and Aleafia Health Enter Exclusive Agreement to Support Medical Cannabis Coverage for Members
  • BevCanna’s Pure Therapy Reports Record Monthly Revenue
  • CBD Vaping: Why So Many People Have Started
Facebook Twitter Instagram LinkedIn Youtube

DMO PRO Subscription

  • πŸ“Š Free vs. Pro
  • πŸ“« Register
  • πŸ‘€ My Account
  • πŸ’³ Payment History
  • πŸ”‘ Recover Password
  • πŸ”“ Login
  • πŸ”’ Logout

Cannabis News by Region

  • πŸ‡ΊπŸ‡Έ United States
  • πŸ‡¨πŸ‡¦ Canada
  • πŸ‡¬πŸ‡§ United Kingdom
  • 🌏 Asia
  • 🌍 Europe
  • 🌎 Latin America
  • 🌏 Oceania and Australasia

Cannabis Tools & Resources

  • πŸ“… Calendar
  • πŸ“Š Databases
  • πŸ“‡ Directories
  • πŸ“™ Glossary
  • πŸ”” RSS Feeds
  • πŸ“Ί Videos

Find Cannabis Business Services

  • βš–οΈ Attorneys & Law Firms
  • πŸ“Š Accountants & Accounting Firms
  • πŸ’‘ Consultants & Consulting Firms
  • πŸ“² Marketing Agencies & Firms

The Daily Marijuana Observer

  • Subscribe
  • About MJobserver.com
  • Affiliate Marketing Disclosure
  • Legal Disclaimer
  • Privacy Policy
  • Contact Us

Advertise with Us

  • πŸ‘€ Advertise
  • πŸ“£ DMO Newswire
  • πŸ“‡ List in Our Databases

Β© 2018 - 2020 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observerβ„’ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

No Result
View All Result
  • Home
  • Latest
  • πŸ”’ PRO
    • πŸ”’ A.M. Watchlist
    • πŸ”’ Analyst Action
  • πŸ’Ό Business
  • πŸ“ˆ Investments
    • πŸ“ˆ Stocks
    • πŸ’° ETFs and Funds
    • πŸ’­ Market Commentary
    • πŸ“° Press Releases
    • πŸ“… Earnings Calendar
  • βš–οΈ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • πŸ‘₯ People
    • ⚽ Athletes
    • πŸ’Ό Executives
    • 🌟 Celebrities
    • πŸ›’ Consumers
    • βš•οΈ Doctors
    • πŸ’Š Patients
  • πŸ’Š Health
  • πŸ“‡ Databases
    • πŸ“ˆ Stock Databases
    • πŸ’° Fund Databases
    • πŸ’Ό Service Providers Databases
    • 🏦 Marijuana Stock Brokers
    • πŸ’² Marijuana Cryptocurrencies

Β© 2018 - 2020 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observerβ„’ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.